BioMarin Pharmaceutical Inc. And Serono, Inc. Announce Data On Phenoptin In PKU To Be Presented At The 56th Annual Meeting Of The American Society of Human Genetics

NOVATO, California, and GENEVA, Switzerland, September 12 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN , SWX: BMRN) and Serono (virt-x: SEO and NYSE: SRA) today announced data from clinical studies of Phenoptin(TM) (sapropterin dihydrochloride), an investigational oral small-molecule therapeutic for the treatment of phenylketonuria (PKU), that will presented at the 56th Annual Meeting of the American Society of Human Genetics (ASHG) being held in New Orleans, Louisiana, October 9 to 13, 2006. Data to be presented is summarized below.